Skip to main content

Table 2 Khorana risk score and Khorana risk group evaluated among the PROTECHT patients

From: Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study

 

Nadroparin (N = 765*)

Placebo (N = 378*)

Khorana Risk score

  

   0

38.2 (292/765)

36.8 (139/378)

   1

32.2 (246/765)

30.4 (115/378)

   2

21 (161/765)

21.7 (82/378)

   3

8 (61/765)

9.8 (37/378)

   4

0.5 (4/765)

1.1 (4/378)

   5

0.1 (1/765)

0.3 (1/378)

Khorana Risk group*

  

   High risk

8.6 (66/765)

11.1 (42/378)

   Intermediate risk

53.2 (407/765)

52.1 (197/378)

   Low risk

38.2 (292/765)

36.8 (139/378)

  1. Data are % (N) unless otherwise indicated. *For 4 patients in the nadroparin group and 3 patients in the placebo group evaluation of Khorana risk score has not be perform due to missing information for the variables(site of cancer, platelet count, haemoglobin level, leukocyte count and body mass index).
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us